Syncom Formulations (India) Limited (SYNCOMF) fundamentals
Syncom Formulations (India) Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SYNCOMF (ISIN INE312C01025). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Syncom Formulations (India) Limited does
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and markets more than 200 pharmaceutical formulation products in various dosage forms, like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections and Dry Vial injections, Dry Syrups, Ointments and Inhalers. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Albendazole Oral Suspension USP 100mg, Cetirizine Oral Solution BP, Clotrimazole Cream USP, Compound Benzoic Acid Ointment BP, and others.
Valuation and market data
| Last close | ₹19.46 |
|---|---|
| Market capitalisation | ₹1,688 crore |
| Enterprise value | ₹1,699 crore |
| P/E (TTM) | 0.00 |
| Price to book | 4.93 |
| Price to sales (TTM) | 3.18 |
| Book value per share | ₹3.95 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Nov 18 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹518 crore | ₹101 crore | ₹76 crore | 0.00 |
| Mar 2025 | ₹480 crore | ₹65 crore | ₹49 crore | 0.57 |
| Mar 2024 | ₹271 crore | ₹32 crore | ₹24 crore | 0.32 |
| Mar 2023 | ₹239 crore | ₹27 crore | ₹20 crore | 0.24 |
| Mar 2022 | ₹232 crore | ₹26 crore | ₹20 crore | 0.26 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 50.6% |
|---|---|
| Foreign institutions (FII) | 0.3% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 49.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.